Yoo Dong Won

Yoo Dong Won

Auto-generated profile, based on publicly available information

Yoo Dong Won

Department of Radiology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2009 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
SKSeok Jung Kim
Seok Jung Kim
YSYong-Woon Shin
Yong-Woon Shin
KYKyu-Hyun Yang
Kyu-Hyun Yang
SKSang-Bum Kim
Sang-Bum Kim
MYMoon-Jib Yoo
Moon-Jib Yoo
SLSoo-Young Lee
Soo-Young Lee
We performed a multicenter, open, randomized, clinical study of autologous cultured osteoblast injection for long-bone fracture, to evaluate the fracture healing acceleration effect and the safety of autologous cultured osteoblasts.

1 November 2021 in Neurointervention
Verified
Journal Article
Open access
PDF file
YIYon-Kwon Ihn
Yon-Kwon Ihn
BKBum-soo Kim
Bum-soo Kim
HJHae Woong Jeong
Hae Woong Jeong
SSSang Hyun Suh
Sang Hyun Suh
YWYoo Dong Won
Yoo Dong Won
Woong YoonWoong Yoon
Woong Yoon
Purpose: To assess patient radiation doses during diagnostic and therapeutic neurointerventional procedures from multiple centers and propose dose reference level (RL).Materials and Methods: Consecutive neurointerventional procedures, performed in 22 hospitals from December 2020 to June 2021, were retrospectively studied. We collected data from a sample of 429 diagnostic and 731 therapeutic procedures. Parameters including dose-area product (DAP), cumulative air kerma (CAK), fluoroscopic time (FT), and total number of image frames (NI) were obtained. RL were calculated as the 3rd quartiles of the distribution.Results: Analysis of 1160 procedures from 22 hospitals confirmed the large variability in patient dose for similar procedures. RLs in terms of DAP, CAK, FT, and NI were 101.6 Gy·cm2, 711.3 mGy, 13.3 minutes, and 637 frames for cerebral angiography, 199.9 Gy·cm2, 3,458.7 mGy, 57.3 minutes, and 1,000 frames for aneurysm coiling, 225.1 Gy·cm2, 1,590 mGy, 44.7 minutes, and 800 frames for stroke thrombolysis, 412.3 Gy·cm2, 4,447.8 mGy, 99.3 minutes, and 1,621.3 frames for arteriovenous malformation (AVM) embolization, respectively. For all procedures, the results were comparable to most of those already published. Statistical analysis showed male and presence of procedural complications were significant factors in aneurysmal coiling. Male, number of passages, and procedural combined technique were significant factors in stroke thrombolysis. In AVM embolization, a significantly higher radiation dose was found in the definitive endovascular cure group.Conclusion: Various RLs introduced in this study promote the optimization of patient doses in diagnostic and therapeutic interventional neuroradiology procedures. Proposed 3rd quartile DAP (Gy·cm2) values were 101.6 for diagnostic cerebral angiography, 199.9 for aneurysm coiling, 225.1 for stroke thrombolysis, and 412.3 for AVM embolization. Continual evolution of practices and technologies requires regular updates of RLs.

1 May 2006 in Clinical Radiology
Verified
Journal Article
Closed access
PDF file
HSH.-H. Song
H.-H. Song
YWY.-D. Won
Y.-D. Won
YKY.-O. Kim
Y.-O. Kim
SYS.-A. Yoon
S.-A. Yoon

15 July 2016 in Trials
Verified
Journal Article
Open access
PDF file
DIDong Jin Im
Dong Jin Im
YKYun-hyeon Kim
Yun-hyeon Kim
KCKi Seok Choo
Ki Seok Choo
JKJoon-Won Kang
Joon-Won Kang
JJJung Im Jung
Jung Im Jung
BCByoung Wook Choi
Byoung Wook Choi
With the development of computed tomography (CT) technology, coronary CT angiography can be acquired with low doses of radiation and contrast agent without a loss of diagnostic performance. The primary objective of the CONCENTRATE study is to prove the noninferiority of the enhancement effect of low-concentration contrast agents compared to a high-concentration contrast agent of the coronary artery and myocardium with coronary CT angiography. The CONCENTRATE study is a prospective, multicenter, noninferiority, randomized trial evaluating the enhancement effect of low-concentration contrast agents (270 and 320 mg iodine/ml) compared with a high-concentration contrast agent (370 mg iodine/ml) in the coronary artery and myocardium of coronary artery CT angiography. The primary efficacy measurement is the enhancement of coronary arteries as measured in Hounsfield units. The target population comprises 318 patients with suspected coronary artery disease who have been referred for clinically indicated nonemergent coronary CT angiography. Eligible participants are randomized for three different concentrations of the contrast agent in a 1:1:1 allocation ratio to one of three arms. The CONCENTRATE trial is a double-blind study, where the subjects and the outcome assessor are blinded to the concentration of the contrast agent used for coronary the CT angiography. Eight clinical sites in Korea are participating in this trial. The CONCENTRATE study will determine whether low-concentration contrast agents are able to provide diagnostic image quality in coronary CT angiography. NCT02549794 . Registered on 14 September 2015.

26 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DLDong Soo Lee
Dong Soo Lee
CKChang Wook Kim
Chang Wook Kim
HKHEE YEON KIM
HEE YEON KIM
YKYoung-Mi Ku
Young-Mi Ku
YWYoo Dong Won
Yoo Dong Won
DSDER SHENG SUN
DER SHENG SUN
Background: We sought to investigate whether serum immune and inflammatory parameters can help to predict distant metastasis (DM) in patients with unresectable hepatocellular carcinoma (HCC) undergoing curative radiation therapy (RT). Methods: A total of 76 RT courses were analyzed. The following variables were included in the analysis: systemic inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), absolute lymphocyte count, lymphocyte-to-monocyte ratio, albumin, albumin-to-alkaline phosphatase ratio, RT-related parameters, and levels of total protein, hemoglobin, α-fetoprotein, and PIVKA-II. Distant control (DC) and overall survival (OS) rates were calculated and compared. Results: The mean age was 61.4 years, and most patients were men (n = 62, 81.6%). The median RT fraction number and fractional doses were 12 (range, 4–30) and 5 (range, 2–12) Gy, respectively. With a median follow-up of 12 (range, 3.1–56.7) months, the 1-year DC and OS rates were 64.4% and 55.2%, respectively. The development of DM significantly deteriorated OS (p = 0.013). In the multivariate analysis, significant independent prognostic indicators for DC and OS rates were the highest posttreatment PLR (≤235.7 vs. >235.7, p = 0.006) and the lowest posttreatment PNI (≤25.4 vs. >25.4, p < 0.001), respectively. Conclusions: Posttreatment serum PLR might be helpfully used as a predictive biomarker of DM in unresectable HCC patients undergoing RT. Future research is necessary to confirm our findings.

10 November 2015 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
PDF file
YKY.M. Ku
Y.M. Ku
SLS.L. Lee
S.L. Lee
YKY. Kim
Y. Kim
YWY. Won
Y. Won